TLDR
- ORMP jumped 14.65% to $4.93 after a detailed shareholder portfolio update today.
- Scilex repayments reached about $118 million, with $43 million still expected.
- Oramed values its Alpha Tau position at roughly $167 million, including warrants.
- Russell 2000 and 3000 inclusion becomes effective at the June 29 market open.
- Oramed reported about $270 million in total cash and assets at March 31, 2026.
Oramed Pharmaceuticals Inc. rose 14.65% to $4.93 after outlining portfolio gains, Scilex repayments, stronger assets, and planned Russell index inclusion. The shareholder update highlighted rising investment values and additional cash expected from Scilex before the end of October 2026. These developments supported the sharp stock advance and strengthened Oramed’s financial position across its expanding investment portfolio.
Oramed said Scilex has returned about $118 million through principal, interest, warrants, royalties, and other payments since the original transaction. The company provided Scilex with a secured loan worth approximately $99.5 million during a financing transaction completed in 2023. It expects another $43 million by October, lifting total anticipated recoveries from the loan arrangement to roughly $161 million.
The company also retains a 4% royalty on worldwide ZTlido sales and related products for another eight years. That royalty gives Oramed continued economic exposure after Scilex completes the remaining scheduled repayments under the secured financing agreement. The transaction could keep producing value beyond the original principal, expected cash collections, and previously received financial benefits.
Oramed Pharmaceuticals Inc., ORMP
Alpha Tau Stake Adds Significant Portfolio Value For Oramed Shareholders
Oramed valued its Alpha Tau Medical position at about $167 million, including warrants, against an original $38.2 million investment. The substantial increase makes Alpha Tau one of the largest and most important assets within Oramed’s diversified strategic investment portfolio. Alpha Tau develops Alpha DaRT, a localized alpha-radiation treatment designed to target solid tumors while limiting surrounding tissue damage.
Alpha Tau recently signed a United States commercialization agreement with Tolmar covering prostate cancer treatment rights and related market development. The agreement includes a $20 million equity investment, manufacturing funding, milestone payments, and a potential expansion into bladder cancer. Alpha Tau will supply treatments to Tolmar while retaining a significant share of the sales economics from each administered treatment.
Clinical progress has strengthened the portfolio position, including pancreatic cancer survival data presented during the ASCO 2026 medical conference. Alpha Tau also received FDA clearance to complete enrollment and add United States sites in its REGAIN glioblastoma study.The company continues five FDA-cleared trials and advances its pivotal skin cancer program toward a planned regulatory submission.
Russell Inclusion and Balance Sheet Strengthen Position Ahead of Reconstitution
Oramed expects to join the Russell 2000 and Russell 3000 indexes through FTSE Russell’s annual market reconstitution process. The inclusion becomes effective at the United States market open on June 29, 2026, according to the company’s update. Management expects the move to improve visibility, broaden market exposure, and support stronger trading liquidity in Oramed shares over time.
The company reported approximately $270 million in total cash and assets as of March 31, 2026, on an unaudited basis. That total includes major portfolio holdings, secured loans, available cash, and several other strategic investments across biomedical and broader markets. Oramed now operates as a diversified company after transferring its oral drug delivery platform and refined insulin program to Lifeward.
Lifeward remains another central holding and develops the ReWalk personal exoskeleton and AlterG anti-gravity rehabilitation systems for mobility patients. Its first-quarter results showed a 33% annual reduction in operating cash burn and 11% growth in ReWalk system sales. Oramed also holds positions in Nano Dimension, BioXcel Therapeutics, Diasome Pharmaceuticals, Hopec Pharma, Ninamed, and income-producing real estate loans.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
